Hospital-Based Infections

Physicians and hospitals are concerned about the problem of hospital-acquired infections, as is the US Centers for Disease Control, which has launched a campaign to prevent antimicrobial resistance in health care settings. Start-ups believe they can help, with effective and rapid tests for infectious disease and narrow spectrum antimicrobials targeted to specific pathogens. buhed ehnwhihOntros sion, acarel

Former movie mogul Samuel Goldwyn once said, "A hospital is no place to be sick," and he was right. The US Centers for Disease Control (CDC) reports that two million patients acquire infections in hospitals each year, and estimates that 90,000 of them die. There are several reasons why hospitals are such prime real estate for microbes. For one thing, many patients are vulnerable because of diseases or treatments that weaken their immune systems. Cancer patients undergoing chemotherapy, transplant patients on immunosuppression drugs, and burn patients are all susceptible to microbes in the environment. Invasive devices—catheters, central lines, ventilators—provide ports of entry for microbes, and in sick patients, common, every day bacteria lurking on skin and other surfaces can have serious consequences.

Even scarier, hospitals are breeding grounds for particularly fearsome infections: life threatening microbes like Pseudomonas aeruginosa, which causes pneumonia, and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Concentra Picks Up Cargo In Latest Troubled Biotech Buyout

 

The Kevin Tang-led firm will pay $4.38 per share for Cargo, which laid off most of its workforce following the failure of a Phase II CAR-T trial.

Venture Funding Plummets In Q2 As Mega-Rounds Falter

 
• By 

Evaluate’s second quarter data show that VC rounds of $100m or more totaled $2.36bn, down from $5.25bn in Q2 of 2024. Overall, the Q2 total dropped year-over-year to $4.92bn from $7.95bn.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By 

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.